The global postmenopausal osteoporosis treatment market was estimated at USD 10.4 billion in 2024 and is projected to reach USD 13.7 billion by 2030, expanding at a CAGR of 4.6% from 2025 to 2030. Market growth is primarily driven by the rising prevalence of osteoporosis among postmenopausal women, coupled with a rapidly aging global population.
Effective treatment options are essential to reduce fracture risk, improve bone density, and enhance overall quality of life among affected patients. Lifestyle factors such as physical inactivity, poor dietary habits, and unhealthy drinking patterns—many of which disrupt hormonal balance—further increase the risk of osteoporosis in women after menopause. As awareness of bone health grows, early diagnosis and long-term disease management are becoming increasingly prioritized in healthcare systems worldwide.
Ongoing advancements in pharmaceutical formulations, along with the introduction of targeted biologics and hormone-based therapies, continue to support market expansion. These innovations aim to improve treatment efficacy, patient adherence, and safety profiles, thereby broadening therapeutic options for postmenopausal women at varying stages of disease progression.
Key Market Trends & Insights
- North America dominated the postmenopausal osteoporosis treatment market, accounting for a 39.4% revenue share in 2024.
- The U.S. led the regional market, contributing 90.9% of North America’s share in 2024.
- By drug class, branded osteoporosis drugs held the largest share at 54.0% in 2024.
- By type, bisphosphonates dominated the market in 2024.
- By distribution channel, retail pharmacies accounted for the largest market share in 2024.
Download a free sample PDF of the Postmenopausal Osteoporosis Treatment Market Intelligence Study by Grand View Research.
Market Size & Forecast
- 2024 Market Size: USD 10.4 Billion
- 2030 Projected Market Size: USD 13.7 Billion
- CAGR (2025–2030): 4.6%
- North America: Largest market in 2024
Competitive Landscape
The postmenopausal osteoporosis treatment market is highly competitive, with major pharmaceutical companies focusing on drug innovation, generic expansion, regulatory approvals, and strategic collaborations to strengthen their market presence.
Key market participants include:
- Teva Pharmaceuticals Industries Ltd.
- Pfizer Inc.
- Merck & Co.
- Novartis AG
- Eli Lilly and Company
- AbbVie Inc.
- Cipla
- Amgen Inc.
- F. Hoffmann-La Roche Ltd.
Recent Developments
- November 2023: Teva Pharmaceuticals received FDA approval for a generic version of Forteo (teriparatide injection) in the U.S. The approval expanded treatment options for postmenopausal women, men with primary or hypogonadal osteoporosis, and patients with glucocorticoid-induced osteoporosis at high fracture risk. The introduction of this generic is expected to enhance treatment accessibility and affordability.
- June 2023: Pfizer announced the reintroduction of DUAVEE (conjugated estrogens/bazedoxifene) in the U.S. market following resolution of packaging issues that led to a voluntary recall in May 2020. The recall did not affect product safety or efficacy. DUAVEE is FDA-approved for managing moderate-to-severe vasomotor symptoms associated with menopause and for the prevention of postmenopausal osteoporosis.
Explore Horizon Databook – the world’s most comprehensive market intelligence platform by Grand View Research.
Conclusion
The postmenopausal osteoporosis treatment market is expected to experience steady growth through 2030, supported by demographic shifts, increasing disease awareness, and continuous pharmaceutical innovation. As healthcare systems emphasize preventive care and long-term bone health management, the demand for effective and accessible osteoporosis therapies will remain strong, positioning the market for sustained development in the years ahead.
No comments:
Post a Comment